Wartość Quick ratio organizacji IMV, Inc. to 2.32
Wskaźnik bieżącej płynności to wskaźnik płynności, który określa, czy firma ma wystarczające zasoby, aby wywiązać się z zobowiązań krótkoterminowych.
The quick ratio is the ratio between quick or liquid assets and current liabilities. Quick assets include those current assets that presumably can be quickly converted to cash at close to their book values. A normal liquid ratio is considered to be 1. A company with a quick ratio of less than 1 cannot at the time fully pay its current liabilities or short-term obligations. This ratio is considered to be a much reliable tool for assessment of liquidity position of companies.
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.